An assessment of emerging molecular farming activities based on patent analysis (2002-2006)

Biotechnology and Bioprocess Engineering

Volumn 13, Issue 3, 2008, Pages 304-312

  Basaran, Pervin ^a,b   Rodriguez Cerezo, Emilio ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

EPO; Patent analysis; Plant molecular farming; Recombinant; USPTO

Indexed keywords

ALPHA GALACTOSIDASE; APROTININ; AVIDIN; CANCER VACCINE; CARORX; CELLULASE; COLLAGEN; CYTOKINE; GLUCOSYLCERAMIDASE; GROWTH FACTOR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HORMONE; IMMUNOGLOBULIN G; INSULIN; INTERFERON; INTRINSIC FACTOR; LACTOFERRIN; LYSOZYME; MILK PROTEIN; MONOCLONAL ANTIBODY; NUTRACEUTICAL; POLYUNSATURATED FATTY ACID; RECOMBINANT ANTIBODY; RHINO RX; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRYPSIN; UNINDEXED DRUG; VACCINE; VETERINARY DRUG; VIRUS VECTOR; VITAMIN;

ARTICLE; BIRD DISEASE; CLINICAL TRIAL; COMMON COLD; CROHN DISEASE; CYANOCOBALAMIN DEFICIENCY; DENMARK; DENTAL CARIES; DRUG MANUFACTURE; EUROPE; FABRY DISEASE; GAUCHER DISEASE; GENE EXPRESSION; GENETIC ENGINEERING; GERMANY; HEPATITIS B; HUMAN; JAPAN; NONHODGKIN LYMPHOMA; NONHUMAN; PATENT; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TRANSGENIC PLANT; UNITED STATES;

EID: 47849128888     PISSN: 12268372     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12257-007-0092-y     Document Type: Article

References (42)

1. Drossard, J. (2004) Downstream processing of plant-derived recombinant therapeutic proteins. pp. 217-230. In: R. Fischer and S. Schillberg (eds.). Molecular Farming. Wiley-VCH, Weinheim, Germany.
2. Foltz, J., B. Barham, and K. Kim (2000) Universities and agricultural biotechnology patents production. Agri-business 16: 82-95.
3. Joly, P. B. and M. A. de Looze (1996) An analysis of innovation strategies and industrial differentiation through patent applications: the case of plant biotechnology. Res. Policy 25: 1027-1046.
4. Science-technology Linkages in an Emerging Research Platform: The Case of Conbinatorial Chemistry and Biology. Electronic Working Paper No. 37. http://ideas.repec.org/p/dgr/umamer/1999020.html.
5. McMillan, G. S., F. Narin, and D. L. Deeds (2000) An analysis of the critical role of public science in innovation: the case of biotechnology. Res. Policy 29: 1-8.
6. Karki, M. M. (1997) Patent citation analysis: A policy analysis tool. World Pat. Inf. 19: 269-272.
7. Oppenheim, C. (2000) Do patent citations count? pp. 405-432. In: B. Cronin and H. B. Atkins (eds.). The Web of Knowledge. Information Today, Medford, NJ, USA.
8. Daim, T. U., G. Rueda, H. Martin, and P. Gerdsri (2006) Forecasting emerging technologies: Use of bibliometrics and patent analysis. Technol. Forecast. Soc. Change 73: 981-1012.
9. Liu, S. J. and J. Shyu (1997) Strategic planning for technology development with patent analysis. Int. J. Technol. Manage. 13: 661-680.
10. Williamson, A. R. (2001) Gene patents: socially acceptable monopolies or an unnecessary hindrance to research? Trends Genet. 17: 670-673.
11. Chau, M., Z. Huang, J. Qin, Y. Zhou, and H. Chen (2006) Building a scientific knowledge web portal: The NanoPort experience. Decis. Support Syst. 42: 1216-1238.
12. Caulfield, T. and B. von Tigerstrom (2006) Gene patents, health care policy and licensing schemes. Trends Biotechnol. 24: 251-254.
13. OECD (2006) Guidelines for the Licensing of Genetic Inventions (http://www.oecd.org/dataoecd/39/38/36198812.pdf).
14. OECD Compendium patent statistics (2003) http://www.oecd.org/sti/ ipr-statistics.
15. Beyond borders: A Global Perspective. The Ernst & Young Global Health Sciences. Biotechnology Report. http://www.ey.com/global/content.nsf/ International/Biotechnology_Library_Beyond_Borders_2004.
16. Primer: Genome and Generic Research, Patent Protection and 21st Century Medicine. BIO Innovation Report. http://www.bio.org.
17. Vain, P. (2006) Global trends in plant transgenic science and technology (1973-2003). Trends Biotechnol. 24: 206-211.
18. Lane, D. P. (2002) Mind the gap. Trends Cell Biol. 12: 541-542.
19. Ramani, S. V. and M. A. de Looze (2002) Country-specific characteristics of patent applications in France, Germany and the UK in the biotechnology sectors. Technol. Anal. Strateg. Manage. 14: 457-480.
20. Baudry, M. and B. Dumont (2006) Comparing firms' triadic patent applications across countries: Is there a gap in terms of R&D effort or a gap in terms of performances? Res. Policy 35: 324-342.
21. Lawrence, S. (2006) Biotech patenting upturn. Nat. Biotechnol. 24: 1190.
22. http://www.nhgri.nih.gov.
23. Lawrence, S. (2004) Patent drop reveals pressures on industry. Nat. Biotechnol. 22: 930-931.
24. Arcand, F. and P. Arnison (2005) Development of Novel Protein-Production Systems and Economic Opportunities & Regulatory Challenges for Canada. http://www.cpmp2005.org/Plant-factories.aspx.
25. Ramani, S. V. (2002) Who is interested in biotech? R&D strategies, knowledge base and market sales of Indian biopharmaceutical firms. Res. Policy 31: 381-398.
26. http://www.gmo-safety.eu.
27. Aggarwal, S., V. Gupta, and S. Bagchi-Sen (2006) Insights into US public biotech sector using patenting trends. Nat. Biotechnol. 24: 643-651.
28. Grandjean, N., B. Charpiot, C. A. Pena, and M. C. Peitsch (2005) Competitive intelligence and patent analysis in drug discovery Mining the competitive knowledge bases and patents. Drug Discov. Today: Technologies 2: 211-215.
29. Torphy, T. J. (2002) Monoclonal antibodies: boundless potential, daunting challenges. Curr. Opin. Biotechnol. 13: 589-591.
30. Farid, S. S. (2007) Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B 848: 8-18.
31. Ma, J. K. C., R. Chikwamba, P. Sparrow, R. Fischer, R. Mahoney, and R. M. Twyman (2005) Plant-derived pharmaceutical - the road forward. Trends Plant Sci. 10: 580-585.
32. Blueprinting for the Development of Plant Derived Vaccines for the Poor in Developing Countries. http://www.biodesign.asu.edu.
33. Yusibov, V., D. C. Hooper, S. V. Spitsin, N. Fleysh, R. B. Kean, T. Mikheeva, D. Deka, A. Karasev, S. Cox, J. Randall, and H. Koprowski (2002) Expression in plants and immunogenecity of plant virus-based experimental rabies vaccine. Vaccine 20: 3155-3164.
34. Ma, J. K., P. M. Drake, and P. Christou (2003) The production of recombinant pharmaceutical proteins in plants. Nat. Rev. Genet. 4: 794-805.
35. Tacket, C. O. (2005) Plant-derived vaccines against diarrheal diseases. Vaccine 23: 1866-1869.
36. http://www.thepoultrysite.com.
37. Commandeur, U., R. M. Twyman, and R. Fischer (2003) The biosafety of molecular farming in plants. AgBiotech Net 5: 1-9.
38. Horn, M. E., S. L. Woodard, and J. A. Howard (2004) Plant molecular farming: Systems and products. Plant Cell Rep. 22: 711-720.
39. http://www.plantpharma.org.
40. Hood, E. E. and J. A. Howard (2002) Plants as Factories for Protein Production. Kluwer Academic Publishers, The Netherlands.
41. Woodard, S. L., J. M. Mayor, M. R. Bailey, D. K. Barker, R. T. Love, J. R. Lane, D. E. Delaney, J. M. McComas-Wagner, H. D. Mallubhotla, E. E. Hood, L. J. Gangott, S. E. Tichy, and J. A. Howard (2003) Maize-derived bovine trypsin: Characterization of the first large-scale, commercial protein from transgenic plants. Biotechnol. Appl. Biochem. 38: 123-130.
42. Chargelegue, N. D., P. M. W. Drake, P. Obregon, and J. K. Ma (2005) Production of secretory IgA in transgenic plants. pp. 159-169. In: R. Fischer and S. Schillberg (eds.). Molecular Farming: Plant-Made Pharmaceuticals and Technical Proteins. Wiley-VCH, Weinheim, Germany.